Drug Discovery, College of Health-related Science and Technology, Taipei Health-related University, 250 Wu-hsing Street, Taipei 11031, Taiwan. Tel: +886 2 2736 1661, Ext 7671; Fax: +886 2 2322 1742; E-mail: [email protected] or C-M Teng, Pharmacological Institute, College of Medicine, National Taiwan University, No. 1, Sector 1, Jen-Ai Road, Taipei 10051, Taiwan. Tel: +886 2 2312 3456 Ext 88310; Fax: +886 two 2322 1742; E-mail: [email protected] Keywords and phrases: lung cancer; HDAC; synergistic; EGFR; apoptosis; erlotinib Abbreviations: EGFR, epidermal growth factor receptor; HDAC, histone deacetylase; TKI, tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer; ERK, extracellular signal-regulated kinase; RTK, receptor tyrosine kinaseReceived 19.4.13; revised 28.7.13; accepted 31.7.13; Edited by M AgostiniSynergistic impact of erlotinib and MPT0E028 M-C Chen et alEGFR-dependent tumor cell development is important, and such strategies could have important clinical impacts. Histone deacetylase (HDAC) inhibitors have already been reported to induce a range of anticancer effects, like tumor cell apoptosis, cell cycle arrest, differentiation, senescence, modulation of immune responses, and altered angiogenesis.13 Quite a few lines of evidence have suggested that combined remedies involving HDAC inhibitors plus TKIs could have synergistic effects in cancer cells.14?6 Vorinostat (also called SAHA; suberoylanilide hydroxamic acid), which is the only HDAC inhibitor at the moment approved as a cancer therapeutic, is applied inside the clinic to treat cutaneous T-cell lymphoma. Additionally, many ongoing clinical trials are assessing the combined use of SAHA and erlotinib in patients with sophisticated NSCLC.17 Not too long ago, we identified MPT0E028 (3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5yl)-N-hydroxy-acrylamide; structure shown in Figure 1c) as a novel potent pan-HDAC inhibitor for use in human tumor cell lines.Buy1314649-82-5 18 In this study, we sought to exploit the antitumor activities of MPT0E028 by testing the hypothesis that therapy with erlotinib in combination with MPT0E028 will overcome the resistance to EGFR inhibitors in erlotinib-resistant lung adenocarcinoma cells.87600-71-3 custom synthesis Our benefits revealed that the combined treatment had synergistic effects on cell viability and also the activations of poly-ADP-ribose polymerase (PARP) and caspase 3 (markers of apoptosis).PMID:24278086 Comparable effects, together with suppression of tumor development, have been observed in an in vivo xenograft model of EGFR inhibitor-resistant NSCLC. These final results indicate that a sensible method to building multi-target anticancer agents determined by a single smaller molecule could substantially improve the success of cancer therapy.Results Cell lines, EGFR status, and inhibition of cell survival by MPT0E028 and erlotinib. We previously tested the growthinhibiting activity of the HDAC inhibitor, MPT0E028, in a diverse panel of cultured NCI-60 human cancer cell lines,18 and identified that the compound is powerful against a broad array of cancer cell types, including lung, ovarian, colon, breast, prostate, and renal cancer cells. Within this study, we examined the effects of erlotinib plus MPT0E028 in erlotinib-resistant NSCLC cells with unique EGFR characteristics.19?2 Based on earlier research, the plasma steady-state concentrations of erlotinib in individuals with advanced solid tumors reached around 4 mM following a each day dose of 150 mg.23,24 As a result, we classified cell lines with IC50 values higher than 4 mM as erlotinib resistant. As anticipated, the IC50 value.